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ABSTRACT
A review of the literature published prior to 2005 concerning cannabis and road crash involvement was conducted,
with emphasis given to studies documenting the relative crash risk associated with driving after use of cannabis.
Case-control studies that have been conducted into cannabis and road crashes have been characterised by
methodological flaws that make the interpretation of the results difficult. Partly as a response to the difficulty of
conducting case-control studies, some researchers have used culpability studies to determine whether cannabis
use contributes to crash involvement. However, as for case-control studies into cannabis and crash involvement,
many culpability studies are difficult to interpret because of methodological problems. There have been two recent
Australian studies that have analysed the relationship between THC (tetrahydrocannabinol - the psychoactive
component of cannabis) measured in the blood and crash culpability. These two studies produced contradictory
results. In summary, the risk of crash involvement associated with driving under the influence of cannabis remains
to be determined. To resolve the issue, it is necessary to conduct a case-control study similar to those that have
been conducted for alcohol. That is, it is necessary to compare the incidence of cannabis in crash-involved drivers
with the incidence in non-crash-involved drivers matched for potential confounding factors, such as age, gender,
time of day, day of week, and direction of travel.
KEYWORDS
Marijuana, Drug effects, Driver performance, Literature review
© The University of Adelaide 2007
The views expressed in this report are those of the authors and do not necessarily represent those of the
University of Adelaide or the sponsoring organisation
CASR Road Safety Research Report | Review of the literature on cannabis and crash risk iii
Summary
Cannabis is a mostly recreational drug that is known to produce dose-related decrements in
performance on a number of laboratory tasks associated with skills that are necessary for
driving. Studies of the effects of cannabis on driving performance (measured with on-road
driving tests and driving simulators) have revealed that it negatively affects a number of
aspects of the driving task but to a lesser degree than it affects performance on laboratory
tasks. Although cannabis is found commonly in the blood of crash-involved drivers, second
in frequency only to alcohol, this is likely to be due to the fact that it is the second most
commonly used drug behind alcohol, and so it is necessary to conduct studies in which the
crash risk associated with driving under the influence of cannabis can be determined.
The best way of determining whether a drug is associated with an increased risk of crash
involvement is to conduct a case-control study in which the drug levels detected in crash-
involved drivers are compared with the levels detected in a matched sample of non-crash-
involved drivers. However, those studies that have been conducted are characterised by
methodological flaws that make the interpretation of the results difficult.
Partly as a response to the difficulty of conducting case-control studies, some researchers
have used culpability studies to determine whether cannabis use contributes to crash
involvement. These studies treat crash-involved drivers who were not culpable for their
crashes as a control group against which to compare the drug use of crash-involved drivers
who were culpable for their crashes. The majority have indicated that cannabis is not
associated with an increased likelihood of culpability. However, as for case-control studies
into cannabis and crash involvement, many culpability studies are difficult to interpret
because of methodological problems. There have been two recent Australian studies that
have analysed the relationship between THC (tetrahydrocannabinol - the psychoactive
component of cannabis) measured in the blood and crash culpability. These two studies
produced contradictory results.
In summary, the risk of crash involvement associated with driving under the influence of
cannabis remains to be determined. To resolve the issue, it is necessary to conduct a case-
control study similar to those that have been conducted for alcohol. That is, it is necessary
to compare the incidence of cannabis in crash-involved drivers with the incidence in non-
crash-involved drivers matched for potential confounding factors, such as age, gender, time
of day, day of week, direction of travel et cetera. Ideally, the drug use of cases and controls
would be compared using the same biological matrix, and potential control group drivers
would not be given the option of not participating. The latter methodological requirement
would need the introduction of a system of mandatory roadside drug testing.
Finally, it is important to emphasise that alcohol is still the most important drug in terms of
its contribution to crash involvement worldwide. Alcohol is found more frequently than
cannabis and other drugs in the blood of crash-involved drivers and analytical studies have
found that the crash risk associated with alcohol far exceeds that associated with drugs.
Furthermore, drug-impaired drivers are frequently also impaired by alcohol, which makes the
risks associated with drugs difficult to isolate from the well-known adverse effects of
alcohol. Nonetheless, research is still needed, particularly a case-control study, to determine
how great a problem cannabis is and whether steps need to be taken to apprehend those
who combine cannabis use and driving.
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1 Introduction
Increasing attention has been devoted in recent years to the issue of driving after the use of
drugs that are known to affect the functioning of the central nervous system. Researchers
have been interested in ascertaining if, and to what extent, such drugs impair driving ability,
and whether their use increases the risk of crash involvement. Driving under the influence
of cannabis has been of particular interest, which is a result of cannabis being found in
surveys to be the most frequently used illicit drug (Australian Institute of Health and
Welfare, 2003; Johnston, O'Malley, Bachman, & Schulenberg, 2004; Miller & Draper, 2001)
and to cannabis being the most frequently detected psychoactive substance, after alcohol,
among driving populations (Bates & Blakely, 1999; Couper & Logan, 2004; Kelly, Darke, &
Ross, 2004; Walsh, de Gier, Christopherson, & Verstraete, 2004).
Of particular importance is research into the relationship between the recent use of
cannabis and involvement in road crashes. If it can be established that driving under the
influence of cannabis is clearly related to crash involvement, as is the case for alcohol
(Borkenstein, Crowther, Schumate, Ziel, & Zylman, 1974; McLean & Holubowycz, 1980),
then policies and methods of enforcement to reduce driving after cannabis use would be
justified. In Victoria, random roadside testing of the oral fluid (saliva) of drivers, to identify
those who have recently used cannabis, is already being practised. The purpose of the
present review is to determine whether the currently available scientific evidence provides a
clear indication of the existence of a positive relationship between driving under the
influence of cannabis and road crash involvement.
The present review, which outlines the findings of research published prior to 2005, begins
with a brief description of cannabis and its effects on aspects of functioning thought to be
relevant for driving. Following this, there is a review of the literature concerning studies into
cannabis and crash involvement. There are three types of such studies. First, there are
studies documenting the incidence of cannabis use among crash-involved drivers. Secondly,
there are case-control studies that can be used to estimate crash risks associated with
driving under the influence of cannabis, and, thirdly, there are studies into the relationship
between cannabis use and responsibility (or ‘culpability’) for crashes. The sum of the
evidence provided in these different types of studies into cannabis use and crash
involvement will form the basis for the conclusions that can be drawn at this time regarding
whether cannabis constitutes a major road safety problem.
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2 Cannabis and its effects
Cannabis comes in a variety of forms (marijuana, hashish, hash oil) that are derived from the
plant cannabis sativa. It is usually smoked but can also be ingested in food (Bates & Blakely,
1999). The chief psychoactive compound found in cannabis is Δ9 -tetrahydrocannabinol
(THC). In most forms of cannabis, the content of THC is between 2 and 8 percent by mass
but can reach as high as 20 percent (Drummer, 2004). There is also evidence that the level
of THC in marijuana is increasing (ElSohly et al., 2000), with greater use of cultivation
techniques designed to produce highly potent cannabis. THC produces a range of effects
(stimulating, sedating, hallucinogenic) that make classification of the drug difficult. Although
cannabis is used mostly as a recreational drug, the cannabis-derived compound dronabinol is
used as an appetite stimulant and antiemetic, preventing weight loss in AIDS patients and
treating the nausea and vomiting associated with cancer chemotherapy (Couper & Logan,
2004; Grotenhermen, 2003).
Cannabis has been found to be addicting. It is associated with compulsive craving, drug
seeking and continued use even when the user is experiencing negative social and health
consequences. A degree of physical dependence can occur with cannabis and abrupt
discontinuation of use can cause mild withdrawal symptoms (Couper & Logan, 2004). Such
dependency occurs in 7 to 10 percent of users (Kalant, 2004), which represents a lower
dependency risk than exists for opioids, tobacco, alcohol and benzodiazepines
(Grotenhermen, 2003). Long term negative effects include chronic inflammatory and
precancerous changes in airways, possible precipitation of schizophrenia, a possible link
with depression, and possible functional problems in the offspring of women who smoke
cannabis during pregnancy (Kalant, 2004).
The effects of cannabis peak within 30 minutes of smoking, while the overall ‘high’ tends to
last for two hours. Most effects have dissipated after 3 to 5 hours. Effects following a dose
of dronabinol begin 30 to 60 minutes after ingestion and peak between 2 and 4 hours, with
appetite being stimulated for up to 24 hours (Couper & Logan, 2004).
Experimental (laboratory-based) studies into the effects of cannabis on skills considered to
be necessary for driving have found that it leads to dose-related decrements in tracking,
reaction time, memory and learning, divided attention, sustained attention (vigilance),
perception, thinking and problem solving, and co-ordination (Bates & Blakely, 1999;
Berghaus & Guo, 1995; Couper & Logan, 2004; Department of Environment Transport and
the Regions, 2000; Kelly et al., 2004; Ramaekers, Berghaus, van Laar, & Drummer, 2004).
However, those affected by cannabis are able to successfully compensate for their
impairment when asked to concentrate on simple tasks for brief periods of time (Couper &
Logan, 2004).
Experimental studies do suffer from a potential lack of external validity, however. Real world
drug use may be very different from that practised in the laboratory, and studies not based
on the performance of actual drug users may over-estimate the effects of the drugs
investigated (Vingilis & Macdonald, 2002). It is also not possible to equate decrements in
performance in laboratory tasks with an increased crash risk (Mathijssen et al., 2002; Mura
et al., 2003).
A number of studies have also been conducted in which participants have performed driving
tasks, either in a driving simulator or on the road, after taking doses of cannabis. Impairment
of driving performance has been found to last for up to three hours, with decrements found
in handling performance, reaction time, time and distance estimation, maintenance of lateral
position, co-ordination, and vigilance (Couper & Logan, 2004). Ramaekers et al. (2004) noted
that effects are dose-related and that highly automated behaviours, such as road tracking
control, were more affected by cannabis than more complex driving tasks that require
conscious control.
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However, the level of impairment observed in driving studies has been found to be less
severe than the impairment of individual cognitive or psychomotor skills observed in
laboratory-based studies (Kelly et al., 2004), and a review of driving studies by Smiley (1999)
found that drivers affected by cannabis tended to compensate for their impairment.
Cannabis-affected drivers have a tendency to drive in a less aggressive manner, to be more
cautious, and to be more aware of their impairment than drivers affected by alcohol. Smiley
did also note, however, that the reduced ability to react to unexpected emergencies was
likely to be a problem for cannabis-affected drivers. It has also been reported that
compensation for impairment by drivers affected by cannabis tends to be insufficient,
particularly when driving demands are high or during prolonged driving (Bates & Blakely,
1999; Couper & Logan, 2004; Ramaekers et al., 2004). Robbe (1994) also found that
compensatory behaviour is less evident following larger doses of cannabis. Furthermore,
Ogden and Moskowitz (2004) noted that the compensatory behaviour of cannabis-affected
drivers may also be due to distortion of judgement of time and distance, as much as it is a
response to conscious recognition of impairment.
A consistent finding has been that impairment of driving is far greater when cannabis is
combined with alcohol (Austroads, 2000; Couper & Logan, 2004; Krueger & Vollrath, 2000;
Ramaekers, Lamers, Robbe, & O'Hanlon, 2000). One factor contributing to this may be that
alcohol is associated with a less cautious driving style and so the compensation often
applied by drivers affected by cannabis alone is no longer applied when cannabis is
combined with alcohol (Department of Environment Transport and the Regions, 2000).
As with laboratory studies, there are doubts regarding the validity of driving performance
studies. Safe driving is dependent not only on a driver’s ability to perform but also on that
driver’s behaviour. The former refers to what drivers are capable of doing, whereas the
latter refers to what they actually do. Behaviour, in this sense, includes thrill seeking,
aggression and acceptance of risk. Although, as noted previously, differences in behaviour
related to cannabis use have been found in driving studies, such direct studies of
performance are not capable of providing valid measures of behaviour. Driving simulators
are limited because there is no element of actual risk in a simulated environment. Studies
conducted on public roads are better than simulator studies but drivers are still aware of
being observed and assessed, and so may behave differently than would be the case in a
normal driving situation (Austroads, 2000).
To summarise, cannabis is a popular, largely recreational, drug that reliably produces
decrements in performance on a number of laboratory tasks. Cannabis also negatively
affects driving performance but is often associated with compensation for impairment in the
form of more cautious driving behaviour. Although these laboratory, driving simulator and
on-road driving performance studies are informative, they do not provide any indication of
the extent of driving under the influence of cannabis, or of the relationship between
cannabis use and crash risk. Research that has been conducted to investigate the crash
involvement risk associated with driving after using cannabis is described in Section 3.
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3 Studies into cannabis and crash involvement
This section describes research undertaken to determine whether driving under the
influence of cannabis increases the risk of being involved in a crash. It describes studies
measuring the prevalence of recent cannabis use in crash-involved drivers, followed by
case-control studies directly assessing the risk of crashing associated with cannabis use,
and, finally, studies of the relationship between cannabis use and the likelihood of being
responsible for crashes. First, however, it is necessary to provide background information on
the methods of testing drivers for cannabis that have been used in studies of cannabis and
crash involvement.
3.1 Testing drivers for recent cannabis use
In order to determine whether a driver has used cannabis prior to driving, it is necessary to
detect and measure THC in the driver’s system. There are a number of alternative biological
matrices available for such tests, with the most commonly used being blood, urine, and
saliva. In order to interpret these tests, it is necessary to know about the different time
courses of THC and its metabolites in the different matrices.
Peak plasma concentrations of THC in blood typically exceed 50 ng/ml (25 ng/ml in whole
blood) within 15 minutes of smoking but decline rapidly due to distribution into body tissues
and fat. An hour after consumption, it is rare to get THC plasma concentrations over 10
ng/ml (5 ng/ml in whole blood). A few hours after consumption, blood concentrations are
usually below 2 ng/ml (Drummer, 2004). Within 8 to 12 hours, plasma levels fall below the
limits of quantitation in occasional users (Couper & Logan, 2004).
Unlike alcohol, there is no clear relationship between blood concentrations of THC and
impairment (Couper & Logan, 2004; Grotenhermen, 2003; Kalant, 2004). Illustrating this,
Berghaus, Grass and Sticht (2000) conducted a meta-analysis of experimental drug studies
and demonstrated that for drugs with short resorption times, such as cannabis, the time of
maximum concentration in the blood precedes the time of maximum impairment of abilities
necessary for driving. For a 20 mg dose of cannabis, the time to maximum blood
concentration is 0.3 hours, whereas the time to the highest decrement in task performance
is 0.6 hours (Berghaus et al., 2000). Papafotiou, Carter and Stough (2005) tested driving
ability on a simulator 30 minutes and 80 minutes after participants smoked cannabis. It was
found that impairment from cannabis was greater 80 minutes after smoking, when THC
levels in blood were 5 to 10 percent of their peak. In addition to making it difficult to link
THC blood concentrations with the likelihood of impairment, the rapid decline of these
concentrations means that in investigations of crash-involved drivers, blood testing of the
drivers two hours after the crash will produce underestimates of THC blood levels at the
time of the crash (Swann, 2000). Metabolites of THC last much longer in the blood than THC
itself and offer no indication of impairment, only previous exposure (Bates & Blakely, 1999;
Couper & Logan, 2004; Grotenhermen, 2003; Ogden & Moskowitz, 2004).
Testing of urine will only reveal whether a person has been exposed to cannabis, not
whether they are impaired by it. It can take as long as 4 hours for metabolites to appear in
urine in concentrations sufficient to be detected by an immunoassay. Positive results
indicate use within the previous 1 to 3 days, although this period is longer for heavy chronic
users (Couper & Logan, 2004; Drummer, 2004). The concentration of drugs within a urine
sample can also be influenced by the degree of water intake by the person providing the
sample (Caplan, 2004).
The most accessible matrix for detection of drugs is oral fluid (saliva), which is comprised of
secretions from the submaxillary, parotid and sublingual glands (Walsh, Flegal, Crouch, &
Cangianelli, 2004). The presence of THC in saliva suggests that cannabis has been smoked
or eaten in the previous hour or two, and is, therefore, more likely to be indicative of
impairment (Kalant, 2004). However, whilst blood levels decline continuously after the initial
peak, a person’s oral fluid THC level can continue to fluctuate over time. This makes it
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impossible to predict blood THC levels from levels of THC detected in oral fluid (Huestis &
Cone, 2004). There can also be difficulties collecting sufficient amounts of oral fluid for
testing, as only very small concentrations of cannabis are found in oral fluid (Kintz, Cirimele,
& Ludes, 2000; Walsh, de Gier et al., 2004) and cannabis can cause decreased oral fluid
production (Verstraete, 2004).
It is important also to recognise that passive smoking of cannabis can lead to positive tests
for all three matrices. Exposure to cannabis being smoked by others has been found to
result in positive tests in blood (Cone & Johnson, 1986), urine (Cone et al., 1987) and oral
fluid (Niedbala et al., 2004). The positive tests are only found shortly after exposure,
however. Niedbala et al., (2004), for example, tested the oral fluid of study participants
sitting in an unventilated room in the presence of people smoking cannabis. THC positive
tests were found within 30 minutes of exposure to the cannabis smoke. Those who were
actively smoking cannabis tested positive at higher concentrations of THC, and for the
whole four hour testing session. Therefore, if recent passive exposure can be ruled out, it is
likely that THC positive oral fluid tests indicate recent use (Huestis & Cone, 2004).
3.2 Prevalence of cannabis in crash-involved drivers
Epidemiological studies into drugs and road crashes can be divided into two types. The first
type is descriptive epidemiology, which involves determining the extent of drug involvement
in road crashes. Such studies can provide information about which drugs are the most
commonly involved in crashes and repeated evaluations provide information about changes
in the patterns of drug use and driving. The second type is analytical epidemiology, which
involves determining which drugs are over-represented in road crashes. This is
accomplished by the use of control groups and the calculation of relative crash risks
according to drug use (de Gier, 2004; Vingilis & Macdonald, 2002). This section is concerned
with studies of the first type. Specifically, it is concerned with studies in which researchers
have analysed body fluids of crash-involved drivers to determine the presence or absence of
indicators of recent cannabis use. Therefore, it excludes studies that have not focussed
specifically on drivers (Waller et al., 1997), or that have been based on self-reports of either
crash involvement or drug use (Albery, Strang, Gossop, & Griffiths, 2000; Chipman,
Macdonald, & Mann, 2003; Darke, Kelly, & Ross, 2004; Fergusson & Horwood, 2001;
Gerberich Goodwin et al., 2003; O'Malley & Johnston, 2003).
In most epidemiological studies of drug use and crash involvement, cannabis is the most
frequently detected drug, excluding alcohol, and is found with the greatest frequency
among young males (Bouchard & Brault, 2004; Drummer et al., 2003; Gerostamoulous et
al., 2002; Logan & Schwilke, 2004; Longo, Hunter, Lokan, White, & White, 2000a; Mura et
al., 2003; Terhune et al., 1992; Tunbridge, Keigan, & James, 2001). The finding that cannabis
is detected more often than other drugs in crash-involved drivers is likely to be a reflection
of cannabis being used more commonly than other drugs (Kelly et al., 2004).
However, the matrices used for testing, and the bio-markers used as indications of
cannabis, need to be taken into consideration when interpreting the results (Department of
Environment Transport and the Regions, 2000; Walsh, de Gier et al., 2004). Higher
percentages of cannabis are found when urine is used as the matrix for testing because of
the longer detection window for cannabis that is provided by urine. These high percentages
do not imply that the driver was impaired by cannabis at the time of the crash, however,
because, as noted in Section 3.1, only inactive metabolites are detected in urine. The use of
blood as the matrix for drug analysis provides the opportunity for detecting the psychoactive
component of cannabis, THC, but many studies in which blood was analysed still reported
the presence of cannabis for cases in which only inactive metabolites were detected. When
only THC is taken as an indicator of the presence of cannabis, percentages are lower than
when metabolite presence is included in cannabis positive cases. Table 3.1 provides a
summary of a number of the most recent studies into cannabis and crash involvement. Note
that the presence of cannabis tends to be detected in 10 to 20 percent of cases when
metabolites are used as indicators of cannabis but that when THC is measured separately
6 CASR Road Safety Research Report | Review of the literature on cannabis and crash risk
from metabolites (Drummer et al., 2003; Longo et al., 2000a; Mura et al., 2003),
percentages are more likely to be less than 10 percent. An unusually high prevalence of THC
metabolites was detected in the study by Gerostamoulous et al. (2002), which the authors
thought was due to the hospital used in the study being in close proximity to the inner-city
entertainment districts. A summary of earlier research is provided in a report by the UK
Department of Environment, Transport and the Regions (2000). This report indicated that
cannabis is detected in between 4 and 12% of crash-involved drivers, with higher rates for
fatally injured drivers and in studies measuring metabolites of THC.
Table 3.1 includes three recent studies in which the active component of cannabis, THC,
was measured in the blood of drivers. One was conducted on a sample of fatally injured
drivers (Drummer et al., 2003) and two on injured drivers treated at a hospital (Longo et al.,
2000a; Mura et al., 2003). In Drummer et al.’s (2003) study, blood samples from 3,398
fatally injured drivers from three states (Victoria, New South Wales, Western Australia) were
analysed over a ten year period (1990-1999) for the presence of a number of drugs,
including cannabis. However, it was only possible during the last two years to test for THC,
and so the sample for THC analyses was 1,420 drivers. Of these 1,420 drivers, 121 (8.5%)
tested positive for THC. Fifty eight drivers tested positive for THC only, 43 also tested
positive for alcohol and 20 also tested positive for other drugs. THC concentrations in the
blood ranged from 1 to 228 ng/ml. Cannabis was detected most frequently among
motorcyclists, rather than car or truck drivers, and more frequently in single vehicle, rather
than multiple vehicle, crashes. Alcohol over the legal limit of 0.05 g/100ml was detected in
29 percent of drivers.
Table 3.1
Summary of recent studies into the detection of cannabis in crash-involved drivers
Study Country Driver sample Fluid % cannabis
Drummer et al., 2003 Australia 1,420 fatal blood 8.5% THC,
7.1% metabolite only
Longo et al, 2000a Australia 2,500 injured blood 2.8% THC,
8.0% metabolite only
Mura et al., 2003 France 900 injured blood 10% THC
Brault, Dussault, Bouchard
& Lemire, 2004
Canada 859 fatal urine 18.5% metabolite
Bouchard & Brault, 2004 Canada 855 fatal blood 13.1% metabolite
Del Rio, Gomez, Sancho &
Alvarez 2002
Spain 5,745 fatal blood 2.2% metabolite
Gerostamoulous et al., 2002 Australia 358 injured blood 36% metabolite
Kintz et al., 2000 France 198 injured urine 11.1% metabolite
Logan & Scwilke, 2004 USA 370 fatal blood 12.7% metabolite
Lowenstein & Koziol-
Mclain, 2001
Canada 414 injured urine 17% metabolite
Movig et al., 2004 Holland 110 injured blood or urine 12% metabolite
Tunbridge et al., 2001 UK 1,184 fatal blood 11.9% metabolite
In Longo et al.’s study (2000a), blood samples of 2,500 drivers treated at hospital following a
road crash were analysed for a variety of drugs, including THC. Only 2.8 percent of these
samples were positive for THC, with an additional 8.0 percent positive for metabolites of
THC. Combining drivers testing positive for THC and those only testing positive for
metabolites, 7.1 percent of the total sample tested positive for cannabis only, 3.2 percent
also tested positive for alcohol, and the remaining cannabis-positive drivers, 0.5 percent,
also tested positive for other drugs but not alcohol. Alcohol was detected in 12.4 percent of
drivers, with 10.5 percent at or above the legal limit of 0.05 g/100ml. No range of THC
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concentrations was reported for this study, although an earlier report on the data (Hunter,
Lokan, Longo, White, & White, 1998) stated that 18.6 percent of THC positive cases had
concentrations at or below 1 ng/ml, 42.9 percent of cases were between 1.1 and 2 ng/ml
and the remaining 38.6 percent were above 2 ng/ml. As was found by Drummer et al.
(2003), motorcyclists more commonly tested positive for THC, as did drivers involved in
single vehicle crashes.
Despite this similarity in the findings, Longo et al. clearly found a smaller percentage of
drivers testing positive for THC than was found in Drummer et al.’s study, especially as
some of the THC positive drivers in the Longo et al. study had THC blood concentrations
below 1 ng/ml, which would not have been counted in the study by Drummer et al. One
reason for the difference between these studies in levels of cannabis detection may be that
Longo et al. tested drivers presenting with injuries at a hospital, whereas Drummer et al.
tested drivers who had died in their crashes. It may be that cannabis is more strongly
associated with fatal than non-fatal injury crashes or more strongly with the types of drivers
more likely to be involved in fatal crashes. A comparison of the crash samples used in the
two studies reveals that, compared to Drummer et al.’s sample, the crashes used in Longo
et al.’s study were characterised by a lower percentage of male drivers (58% versus 79%).
In the Longo et al. study, 86 percent of THC only cases were male, so if more males had
been included in the sample, it is likely that the overall percentage of THC cases would have
been higher. Another difference was in the percentage of single vehicle crashes. In the
Longo et al. study, 29 percent of the car crashes and 32 percent of the motorcycle crashes
were single vehicle crashes, while in the Drummer et al. study, the proportion of single
vehicle crashes was 51 percent. In both studies, cannabis was detected more commonly in
the blood of drivers having single vehicle crashes. A further difference was in the
percentage of motorcycle crashes. The study by Longo et al. included 11 percent
motorcyclists compared to 19 percent in Drummer et al.’s study. Motorcyclists were found
in both studies to be more likely to have used cannabis prior to the crash. Indeed, Drummer
et al. found that the highest percentage of cannabis detection for any demographic group
was for motorcyclists aged 22 to 30.
Another factor that could have produced differences across the studies, in terms of the
percentage of THC positive cases, was the possibility that the THC blood concentrations of
the injured drivers in the Longo et al. study decreased between the time of the crash and
the time of testing at the hospital. This time period had a mean of 2.7 hours (SD = 3.0). The
likely effect of this is that a number of drivers with THC in their blood at the time of the
crash would have only tested positive for a metabolite of THC at the time of testing. In
Drummer et al.’s study, all blood tests were carried out within four hours of the crash and,
in cases in which the driver died instantly or very soon after the crash, there would have
been little degradation in the blood THC concentration (Swann, 2000).
In the other study in Table 3.1 in which THC was tested for, Mura et al. (2003) collected
blood samples from 900 drivers attending a hospital in France following a road crash, and
analysed the samples for drugs. THC was found in 10 percent of drivers, with THC being
detected alone in 60 percent of cases and combined with alcohol in 32 percent. Alcohol over
0.05 g/100ml was found in 26 percent of drivers overall. The percentage of drivers found
with THC in their blood in Mura et al.’s study was higher than that found in Longo et al.’s
study, despite the fact that samples for both studies were taken from injured drivers. This
may represent real regional differences in the prevalence of driving after cannabis use.
However, in Mura et al.’s study, the time between the crash and the taking of blood
samples was, on average, 1.8 hours (SD = 0.9), which is a shorter average time than in
Longo et al.’s study (M = 2.7, SD = 3.0). Also, the sample of drivers in Mura et al.’s study
had a higher percentage of males (74%) than the sample used by Longo et al. (58%). As
noted earlier, male crash-involved drivers tend to be more likely to have cannabis detected
in their blood.
Therefore, the percentage of crash-involved drivers found to have THC in their blood
depends on the nature of the sample, particularly with respect to the proportion of male
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drivers, motorcycle riders and single vehicle crashes. The time taken between the
occurrence of a crash and the taking of a blood sample from an injured driver would also
affect the detection of THC. THC has been found in a significant proportion of crash-involved
drivers but not more than 10 percent, and clearly less than the percentage found with illegal
levels of alcohol in their blood. Also, a significant proportion of drivers testing positive for
cannabis also test positive for alcohol.
Although it is useful to conduct studies in which the extent of drug use by crash-involved
drivers is examined, such studies provide no information on the relative risk of crash
involvement when driving after drug use. In order to determine whether a drug increases
the risk of crash involvement, it is necessary also to measure the extent of drug use by
drivers not involved in crashes. If the level of a drug detected among crash-involved drivers
significantly exceeds the level detected among the general driving population, then it can be
concluded that use of the drug increases the risk of crash involvement. Such ‘case-control’
studies are the focus of the next section.
3.3 Case-control studies
As noted by Chipman et al. (2003), case-control studies for drugs and crash involvement are
difficult to carry out. Samples for toxicological analysis are difficult and expensive to obtain,
particularly from non-crash-involved drivers. There can also be legal barriers to the collection
of control data in some jurisdictions (Walsh, de Gier et al., 2004). For these reasons, there
are relatively few case-control studies concerning drug driving that have been reported in
the literature.
One recent case-control study was conducted in Quebec, Canada (Brault et al., 2004;
Dussault, Brault, Bouchard, & Lemire, 2002). This study compared the level of drugs
detected in fatally injured drivers with that detected in the general driving population using
roadside surveys. Both blood and urine were collected from fatally injured drivers (cases),
and breath, urine and saliva samples were collected from non-crash-involved drivers
(controls). Dussault et al. (2002) compared the results of urine analyses for 354 cases and
5,931 controls. Cannabis was detected in 19.5% of cases and 6.7% of controls. The odds
ratio for all cannabis cases (including those in which other drugs or alcohol were involved)
was 4.6 but for cannabis alone it was 2.2. Among other drugs used alone, greater odds
ratios were found for alcohol between 0.05 and 0.08 g/100ml (3.7), alcohol over 0.08
g/100ml (39.2), cocaine (4.9) and benzodiazepines (2.5). Very high risks were associated
with combinations of drugs (including alcohol) (Dussault et al., 2002).
One possible problem with this study, which was acknowledged by the authors, is that the
results may have been affected by selection bias. As noted by Walsh et al. (2004), refusal
rates in roadside surveys can have a profound effect on the results. Illicit drugs are used by
a small number of drivers and it is common in roadside surveys to get a refusal rate that
exceeds the proportion of drivers testing positive for drugs. If drug use is over-represented
in the drivers refusing to take part in the survey, there will be a bias towards less drug use
being detected in the control group, and, hence, greater odds ratios for drug use by crash-
involved drivers (Bates & Blakely, 1999; Keall & Frith, 2004; Ogden & Moskowitz, 2004;
Walsh, de Gier et al., 2004). In Dussault et al.’s study, 84.6% of potential controls agreed to
providing a fluid sample (saliva or urine). Although this is a high proportion of motorists
agreeing to participate, the proportion not participating is still large enough to markedly
affect the results. Jonah, Boase, Mann, Brands, Macdonald and Stoduto (2004) argue that if
half of those refusing to participate in this study had been positive for cannabis then the true
odds ratio for cannabis would not have been significantly different from 1.0. Dussault et al.
argue that selection bias would not have been great in their study, citing a high percentage
of cannabis detected among young control drivers (24.3% of 16-19 year olds and 22.4% of
20-24 year olds).
An additional problem with Dussault et al.’s study, which was also acknowledged by the
authors, is that cannabis was measured in urine and not blood. Thus, only inactive
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metabolites of cannabis would have been detected, rather than the active component, THC.
This means that the study results for cannabis effectively represent a case-control study for
cannabis users rather than for cannabis impairment when driving. That is, it measures the
relative risk of crashing for drivers who use cannabis at all, rather than measuring the
relative risk of crashing for drivers who are affected by cannabis when driving.
Nonetheless, the study had a number of strengths, such as the measurement of drug use
among non-crash-involved drivers, and case-control comparisons using the same matrix for
drug detection. The results suggest the possibility of a small increase in crash risk with
cannabis but not as great as the risk increase associated with alcohol or with the
combination of two or more drugs. The authors also emphasise that alcohol remained the
most problematic drug, with blood alcohol concentrations in excess of 0.08 g/100ml being
found in nearly 30 percent of fatally injured drivers (Dussault et al., 2002).
Another case-control study into drug use and crash involvement was conducted in France by
Mura et al. (2003), using a similar method to that of an earlier French study (Marquet et al.,
1998). In the Mura et al. study, referred to previously in Section 3.2, blood samples were
taken from 900 injured drivers presenting at hospitals (cases) and 900 patients presenting at
the same hospitals for non-traumatic medical problems, excluding admission for intoxication
(controls). Control group participants all held driver’s licences and were matched to the case
group according to age and gender. The use of blood enabled detection of THC, so that
impairment could be inferred from cannabis-positive results (Mura et al., 2003).
It was found that THC was detected in 10 percent of cases and 5 percent of controls.
Consistent with reports that cannabis use is more common in younger adults, the
percentages for those aged between 18 and 27 were 14.1 percent for cases and 6.7
percent for controls, giving an odds ratio of 2.5. However, cannabis was not over-
represented in cases in older age groups. This contrasts with alcohol, which was over-
represented among cases for all age groups. Another contrast was found between cannabis
and alcohol when results were analysed according to drug concentration. For alcohol, odds
ratios for crash involvement increased with increasing blood alcohol concentration.
However, for cannabis detected in participants under the age of 27, the odds ratio for THC
concentrations above 1 ng/ml was 2.5, and that for THC concentrations less than 1 ng/ml
was 2.7. The authors explained this by referring to the lack of relationship between THC
concentrations in blood and impairment, and, more specifically, to the fact that peak clinical
effects of cannabis occur after blood levels have declined substantially from their peak.
Among other findings, alcohol alone (> .05 g/100ml) was found most commonly (17.0% of
cases, 5.0% of controls, odds ratio = 3.8), benzodiazepines were found to be common
(9.4% of cases and 5.8% of controls, odds ratio = 1.7), morphine was found to have an
odds ratio of 8.2 (2.7% of cases, 0.3% of controls), and the combination of alcohol and
cannabis for drivers under the age of 27 was found to have an odds ratio of 4.6 (9.5% of
cases, 2.2% of controls) (Mura et al., 2003).
There is one clear methodological flaw with the study by Mura et al (2003). This is that the
control group consisted of non-traumatic patients at hospital rather than non-crash-involved
drivers. This violates the case-control study principle that controls should be representative
of the population from which the cases arise (Jamrozik & English, 1991). The use of hospital
patients rather than non-crash-involved drivers is problematic for two reasons. The first of
these is that the control group would ideally provide information about the number of drivers
on the road who had used drugs prior to driving. The use of a group of patients in a hospital
tells us nothing about the drug use of drivers and so does not provide the information
required for calculations of the relative risks for crash involvement. The second problem is
that people presenting at a hospital with non-traumatic medical complaints are likely to be a
particular group of people who are not representative of the general population. How this
relates to their likelihood of using drugs in the period prior to their appearance at a hospital is
unclear. Mura et al.’s study provides very useful information about the prevalence of drugs
in crash-involved French drivers but the fact that the controls were not driving at the time of
their blood being taken makes it difficult to interpret the odds ratios derived from the study
data.
10 CASR Road Safety Research Report | Review of the literature on cannabis and crash risk
Another European case-control study was a study conducted by Movig et al. (2004) in
Tilburg, Netherlands. In this study, 110 drivers sustaining injuries requiring hospitalisation
provided either urine or blood samples (cases) and 816 non-crash-involved drivers were
recruited at roadside surveys and provided a sample of urine or blood (controls). Cannabis
use was determined on the basis of the presence of THC metabolites, which, as previously
noted, provide no indication of impairment. It was found that cannabis was detected in 12
percent of cases and 6 percent of controls. These percentages, after controlling for potential
confounders, produced an odds ratio of 1.22, which was not significantly different from
zero. Significantly elevated odds ratios were found for benzodiazepines (5.1), alcohol at a
concentration between 0.05 and 0.079 g/100ml (5.5), alcohol over 0.08 (15.5), drug
combinations (6.1), and drugs combined with alcohol (112.2) (Movig et al., 2004).
Again, there are methodological problems with the study. First is that, similarly to Dussault
et al’s (2002) study, there may be selection bias. The controls represented 79 percent of
those approached to participate. Thus, the percentage not participating (21%) was greater
than the percentage testing positive for cannabis (6% of controls). Movig et al. did address
this problem, reporting that there were no major differences in the age, gender or alcohol
levels of those agreeing to participate and those potential controls who declined. The
alcohol levels were available because the roadside drug surveys were done in conjunction
with random breath testing sessions operated by the police.
Ramaekers et al. (2004) argued that the lack of a significant finding in the study by Movig et
al. (2004) for cannabis was due to a small sample size. Movig et al. acknowledged the small
sample size and the resulting wide confidence intervals around the odds ratios but did not
think that a greater number of cases would have altered their findings. Specifically, they
claimed that the confidence intervals would have decreased in size with a larger sample of
cases but that the point estimates of odds ratios would have remained the same. That is,
according to the authors, the odds ratio of 1.22 for cannabis would not have changed but
the width of the confidence interval (0.55-2.73) would have decreased. Movig and
colleagues are continuing with the study to increase the sample.
A more important problem with the study by Movig et al. (2004) is related to the choice of
matrices for drug analysis. The researchers opted to collect either blood or urine, so that the
inclusion of participants was not limited by the choice of only one biological fluid. The
problem with this method was that 39 percent of cases provided urine samples and 61
percent provided blood, compared to 85 percent urine and 15 percent blood for the controls.
This meant that comparisons between cases and controls were not using the same
measurement techniques. It is a principle of case-control studies that any errors in
measurement of exposure be non-differential between cases and controls. Failure to
achieve this can cause ‘information bias’ (Wacholder, McLaughlin, Silverman, & Mandel,
1992). In the case of cannabis, its metabolites last longer in urine than in blood and the
greater use of urine for the control group would lead to a greater chance of cannabis being
detected for the controls than for the cases. This, in turn, would be likely to lead to under
estimation of the relative crash risk associated with driving after cannabis use. Movig et al.
(2004) deny the likelihood of information bias by referring to the detection of cannabis in 7.3
percent of blood specimens but only 6.3 percent of urine specimens (the opposite of what
would be expected if cannabis was too readily detected in urine compared to blood).
However, in a study in which participants decided whether they would provide blood or
urine, these results may reflect qualitative differences in the types of control drivers who
opted to provide blood compared to the drivers who opted to provide urine.
A case-control study was conducted in Victoria, Australia by Haworth, Vulcan, Bowland and
Pronk (1997). This study was concerned with single vehicle crashes within 200 km of
Melbourne, Victoria. Driver and vehicle characteristics were recorded for 127 cases and 865
controls, with cannabis measured in urine for cases and by self-report for controls. Cannabis
alone was found in the urine of 4 percent of cases, and in combination with alcohol
(assessed with breath tests) in 18 percent of cases. Among controls, cannabis was only
reported by one percent of drivers. The odds ratio for crash involvement associated with
cannabis, after adjustment for age and blood alcohol concentration, was 38. This very high
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odds ratio, however, is likely to have been inflated by the method used in the study to
assess cannabis use. Measurement of cannabis in urine for cases would have resulted in
drivers who had consumed cannabis any time in the few days prior to the crash being
counted as cannabis cases. For controls, there is a strong possibility that there was under-
reporting of cannabis use. Therefore, the likelihood of cannabis use being overestimated
among cases and underestimated among controls would have produced an inflated odds
ratio.
In summary, there have been a small number of recent case-control studies conducted to
determine the relative risks for crash involvement associated with driving after use of drugs
including cannabis (Dussault et al., 2002; Movig et al., 2004; Mura et al., 2003). Dussault et
al. found cannabis use to produce approximately a twofold risk of crashing, Mura et al. found
a two to threefold crash risk related to cannabis only for those aged under 27, and Movig et
al. failed to detect an increased risk associated with cannabis. In all studies, alcohol and
combinations of drugs far exceeded cannabis in their effects on crash risk. However, in all
three studies, methodological problems mean that great caution must be exercised in
interpreting the results. The studies by Dussault et al. and Movig et al. were both potentially
affected by selection bias and the use of urine for drug testing, meaning that only the
inactive metabolites of THC could be detected. Mura et al.’s study did not use a sample of
drivers for a control group. The most recent Australian case-control study (Haworth et al.,
1997) was concerned only with single vehicle crashes and measured cannabis use in a way
that would have greatly inflated the odds ratio for crash involvement associated with
cannabis.
These methodological problems emphasise the difficulties of conducting case-control
studies designed to investigate drug driving. Compromises are often necessary for studies
to proceed. Other case-control studies being conducted in Norway (Assum, 2004) and the
United Kingdom (Buttress, Tunbridge, Oliver, Torrance, & Wylie, 2004) have run into
considerable operational difficulties. These difficulties associated with case-control studies
have led some researchers to investigate the risk of crash involvement associated with
drugs by using a methodology that does not rely on collecting control data in addition to
case data. These studies, based on assessments of the relationship between drug use and
crash responsibility (or ‘culpability’), are discussed in the following section.
3.4 Crash culpability studies
Studies of this sort involve classifying crash-involved drivers according to their degree of
responsibility (or ‘culpability’) for the crash. The drug use of drivers culpable for their crashes
is then compared with the drug use of drivers judged not to be culpable. If greater use of a
drug is evident among drivers culpable for their crashes, then that drug is linked to a greater
crash risk. Culpability studies treat crash-involved drivers who are not culpable for their
crashes as a control group, based on the assumption that a driver’s likelihood of being
involved in a crash as a non-culpable party is determined by the amount of driving they do.
That is, involvement in crashes for which one is not culpable is treated as a measure of
driving exposure (Bates & Blakely, 1999).
Judgement of culpability is usually based on a set of pre-determined criteria that allow for
the effects of mitigating factors (e.g. other drivers’ actions, bad weather) to be taken into
account. This must be done by assessors blind to the drug use status of the drivers
(Robertson & Drummer, 1994).
Early culpability studies tended to find that cannabis was not associated with an increased
crash risk (Drummer, 1994, 1995; Terhune, 1982; Terhune et al., 1992; Williams, Peat,
Crouch, Wells, & Finkle, 1985). Terhune et al. (1992) conducted a culpability analysis on
1,882 fatal crashes in the United States. Alcohol was present in 51.5 percent of drivers and
cannabis was found in 6.7 percent. Two thirds of the cannabis positive drivers were also
positive for alcohol. Drivers positive for cannabis only were not found to have an increased
likelihood of culpability for the crash (the non-significant trend was actually in the opposite
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direction). Increased levels of crash culpability were found, however, for alcohol, and for
alcohol combined with other drugs. The combination of cannabis and alcohol was related to
a greater likelihood of crash culpability but no greater than for alcohol alone. It was
concluded that the relationship between crash culpability and the combination of cannabis
and alcohol was due to the dose-dependent effects of alcohol. Drummer (1994) also looked
at fatal crashes, but in Australia, and found that cannabis (found in 11 percent of drivers)
was not linked to a greater likelihood of crash culpability. Again, the non-significant trend for
cannabis was in the opposite direction, whereas alcohol (36 percent of drivers) and alcohol
combined with cannabis were associated with greater crash culpability. Adjusting the odds
ratios for age and gender did little to change the results (Drummer, 1995). However, the
Drummer studies only measured metabolites of cannabis rather than THC and so, in many
cases, the drivers included in the cannabis positive group would not have been impaired at
the time of the crash.
More recent culpability studies that have considered the role of cannabis in crashes have
been conducted in Australia by Longo et al. (2000b) and by Drummer et al. (2004). Studies
overseas into cannabis and crash culpability have been conducted in Canada (Dussault et al.,
2002) and the United States (Lowenstein & Koziol-Mclain, 2001).
Longo et al. (2000b) investigated the relationship between drugs and crash culpability in a
sample of 2,279 non-fatally injured car drivers and motorcycle riders who were treated at
hospital in Adelaide, South Australia. This study used the culpability method devised by
Robertson and Drummer (1994), which adjusts culpability levels according to eight
mitigating factors. Using this method, 55 percent of the injured drivers were designated as
culpable, 39 percent as non-culpable and 6 percent as ‘contributory’. To make the analysis
simpler, the drivers who merely contributed to the crash but were not judged to be culpable
were excluded. Compared to the drug-free group, greater culpability was found for those
drivers testing positive for alcohol, benzodiazepines, alcohol combined with cannabis, and
alcohol combined with benzodiazepines. THC alone was not found to be associated with
greater culpability. Instead, similar to the earlier studies noted above, there was a non-
significant trend toward lower culpability for THC positive drivers. The relationship with
culpability for the combination of alcohol and cannabis was no greater than that for alcohol
alone, again suggesting that alcohol is the factor increasing crash risk when people drive
when affected by both alcohol and cannabis. Longo et al. (2000b) were able to dismiss any
concerns about a small sample size being responsible for not finding a relationship between
THC and crash capability. The failure to find greater crash culpability for the 44 drivers
testing positive for THC only was contrasted with the finding of a greater likelihood of
culpability for the 46 drivers testing positive for benzodiazepines only. The results also
remained the same after adjusting for potentially confounding factors, such as age and
gender (Longo, 2001).
Another Australian study was conducted by Drummer et al. (2004), using blood analyses of
drivers fatally injured in road crashes in Victoria, New South Wales and Western Australia
over ten years. As noted in Section 3.2, Drummer et al. analysed 3,398 blood samples but
only 1,420 were analysed for THC, beginning when the necessary technology became
available. For the entire sample, 79 percent were classified as being culpable for the crash,
15 percent were classified as not culpable, and 6 percent as contributory. The latter group
was excluded from analyses. The drivers with the highest odds ratios for crash culpability
(with potentially confounding factors controlled) were those with a blood alcohol
concentration above 0.05 g/100ml, and those aged from 18 to 25. With regard to cannabis,
drivers testing positive for THC alone were found to have an elevated likelihood of being
culpable for their crashes. The combination of alcohol and cannabis was also found to have a
greater odds ratio for crash culpability than alcohol alone, which the authors interpreted as
indicating that cannabis increases the impairment associated with alcohol. Metabolites of
THC were not found to be linked to crash culpability. Drummer et al. also analysed results
according to drug concentration and found an elevated odds ratio for culpability among
drivers with blood THC concentrations above 5 ng/ml. Furthermore, they argued that the
relationship between THC and crash culpability “showed a biological gradient, similar to that
observed for alcohol” (Drummer et al., 2004, p245). This last conclusion was based on a
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comparison of the culpability of 49 drivers with THC blood concentrations above 5 ng/ml and
9 drivers with concentrations below that level.
As was the case for the incidence of drugs and driving (see section 3.2), the studies by
Longo et al. (2000b) and Drummer et al. (2004) produced very different findings. Drummer
et al. argue that the different results are due to the lower THC concentrations detected in
the Longo et al. study. According to Drummer et al., the main risk from THC comes when it
is consumed in sufficient quantities to produce a blood concentration above 5 ng/ml. Few
drivers in the Longo et al. study recorded THC concentrations at this level. In interpreting
their results, Longo et al. did note that the majority of THC concentrations found in the blood
samples collected were in the very low range relative to the levels that can be reached by
cannabis users. Caution was therefore advised in accepting the lack of a relationship
between cannabis and crash culpability (Longo et al., 2000b). However, there are three
reasons why some degree of confidence can still be placed in the findings.
First, as previously noted in Section 3.2, there is little relationship between THC
concentrations in the blood and impairment, so those drivers with low THC readings may
have been as impaired as those with higher readings. Secondly, the long time in many cases
between the crash and the taking of blood (M = 2.7 hours, SD = 3.0) would have resulted in
lower THC concentrations than would have been the case at the time of the crash. Some of
the drivers only testing positive for the metabolite may have tested positive for THC at a low
concentration if their blood sample had been taken earlier. Therefore, although the study
may underestimate the prevalence of THC in crash-involved drivers, it would be more likely
to detect a relationship, if one exists, between THC, even at low concentrations, and crash
culpability. Thirdly, the results are consistent with previous findings of no increased
likelihood of culpability with cannabis use. Although previous studies had chiefly assessed
metabolites of cannabis, it is likely that a proportion of drivers positive for cannabinoid
metabolites would have been impaired by THC at the time of the crash.
This latter point may also be relevant for raising questions about the findings of Drummer et
al.’s (2004) study. Specifically, there is an apparent inconsistency between the earlier study
finding no relationship with crash culpability for metabolites of cannabis (Drummer, 1994,
1995), and later studies finding the opposite for THC (Drummer, 1999; Drummer et al.,
2004). As noted in a report by Austroads (2000), it would be expected that some of the
drivers in the earlier data set who tested positive for metabolites would also have tested
positive for THC if such an analysis had been conducted. If THC is associated with an
increased likelihood of crash culpability, as found in the more recent study, then it would be
expected that there would have been a (smaller) relationship between testing positive for
cannabis metabolites and greater crash culpability in the earlier study. That this was not the
case and instead, that the trend, which was approaching significance, was in the opposite
direction suggests that the cannabis problem, if one exists, must not be a large one
(Austroads, 2000).
Bates and Blakely (1999) argue that findings such as those from Drummer’s early study
suggest that THC may reduce the likelihood of crash culpability. In Drummer’s early study,
drivers only positive for metabolites of THC were classified as cannabis positive when they
should have been classified as drug free. As the drug free group was given the culpability
odds ratio of 1.0, the wrongful inclusion of any drug free drivers in a drug group would move
the odds ratio for the group closer to 1.0. That is, there would be a reduction in the odds
ratios for drugs that increase the likelihood of culpability, and an increase in the odds ratios
for any drugs that reduce the likelihood of culpability. As the odds ratio for culpability for the
cannabis group was less than 1.0, and the inclusion of metabolite positive only drivers
would have moved the odds ratio closer to 1.0, it is possible that the odds ratio for THC
positive drivers was less than that found in the study for the cannabis group. It may have
been significantly less than 1.0. That is, it may be that the drivers impaired by THC were
significantly less likely to be culpable for their crashes (Bates & Blakely, 1999).
In any case, there does at least appear to be some degree of inconsistency in the two
Drummer studies, with the later one finding increased culpability for THC and the earlier one
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finding no sign of increased culpability for cannabis users (those positive for metabolites,
some of whom would likely have been positive for THC). Alternative explanations for this
combination of apparently inconsistent results are that the risks associated with THC have
changed in a few years, that the proportion of cannabis users choosing to drive when
positive for THC (i.e. when actually impaired by cannabis) has increased sharply, or that the
incidence of drivers testing positive for THC and who were culpable for the crash in either
one of the data sets was “a statistical aberration” (Austroads, 2000, p17).
Two other studies that included analyses of cannabis use and crash culpability were those
conducted in Canada by Dussault et al. (2002) and in the United States by Lowenstein and
Koziol-Mclain (2001). Unfortunately, these two studies are unable to provide a solution to
the contradictory results of the two Australian studies. This is because both of these studies
only tested for metabolites of THC in urine.
In the study by Dussault et al. (2002), urine analyses of 354 fatally injured drivers were used
to determine the relationship between drug use and crash culpability. The culpability
analysis was done in addition to a case-control analysis (described in Section 3.3) so that the
case-control results could be checked. The case-control results for cannabis indicated an
increased crash risk associated with cannabis use but inconsistent results were found in the
culpability analyses, with no evidence of an increased likelihood of crash culpability for
drivers testing positive for cannabis metabolites. Although the culpability analyses did
confirm the increased case-control crash risks of alcohol and cocaine, the authors attributed
the lack of an association between cannabis use and crash culpability as indicative of the
limitations of culpability analyses and a lack of statistical power.
The other study by Lowenstein and Koziol-Mclain (2001) investigated the culpability and
drug use of 414 non-fatally injured drivers. Approximately half of the drivers were deemed to
be culpable. Cannabis (17%) was detected more frequently than alcohol (14%) in the urine
samples of the drivers. However, only alcohol was found to be associated with a greater
likelihood of crash culpability. The authors interpreted the findings as indicating that
cannabis is not a road safety risk and argued that this may be explained by compensation for
impairment. They did, however, note that the sample was primarily of middle aged drivers
with minor or moderate injuries and that a different sample in terms of age or injury level
may have produced different results.
To summarise the findings of recent culpability studies, only Drummer et al. (2004) found an
increased likelihood of crash culpability associated with cannabis use. Another Australian
study that analysed blood samples, but in hospital treated rather than fatally injured drivers,
(Longo et al., 2000b) found no greater likelihood of crash culpability for drivers testing
positive for THC. Earlier studies and recent ones measuring metabolites of cannabis found
no increased culpability for drivers who used cannabis. Drummer et al.’s findings are
surprising, given that earlier reports by the same authors, grouping together drivers testing
positive for THC and those testing positive for metabolites only, found no increase in
culpability rates for cannabis-using drivers. Nonetheless, the divergent findings of the two
recent Australian studies mean that the issue of cannabis and crash culpability remains
unresolved.
It is also important to note that crash culpability studies are characterised by a number of
limitations. The most obvious limitation of culpability studies is that the non-culpable driver
may still have contributed to the causation of the crash (Austroads, 2000; Keall & Frith,
2004; Lowenstein & Koziol-Mclain, 2001; Vingilis & Macdonald, 2002). For example, a driver
not making a mistake may still contribute to an intersection collision by having not braked
quickly enough. If a drug causes a lengthening of reaction time (i.e. slower reactions), it may
increase the likelihood of a driver being involved in a crash as the non-culpable party. This
would make it less likely that a culpability analysis would find an association between use of
this drug and crash culpability. Alternatively, if a drug is associated with a slower, more
conservative driving style, it may be that use of that drug will decrease the likelihood of a
non-culpable driver striking a vehicle driven by someone making a mistake (such as an
unsafe turn across oncoming traffic). In this scenario, it would be more likely that use of the
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drug would be associated with greater crash culpability. As cannabis has been associated
with both longer reaction times and a slower, more conservative driving style, it is unclear
whether culpability analyses are more or less likely to identify cannabis use as a contributor
to crash involvement. Evidence supporting the possibility that non-culpable crash-involved
drivers are not representative of the driving population (contrary to what is assumed in all
culpability analyses) comes from studies finding elevated blood alcohol concentrations
among this group of drivers (e.g. Neilsen, 1965).
Another possible problem with culpability analyses is that there is a subjective element
involved in the attribution of culpability (Movig et al., 2004). Studies in which the
assessment of culpability relies to some extent on the judgement of police may be biased
by the greater likelihood of police attributing culpability to an impaired driver. This would
result in drugs being more likely to be associated with crash culpability (Keall & Frith, 2004).
The likelihood of misclassification of culpability can be reduced by assessing culpability on a
gradient and eliminating ‘contributory’ drivers (Bates & Blakely, 1999), as was done by both
of the recent Australian studies, and by relying on multiple sources of information for the
determination of culpability.
A final problem with culpability studies is that the lack of a non-crash-involved control group
means a reduction in the sample of crash-involved drivers that can be treated as ‘cases’.
This, in turn, reduces the statistical power available to assess drug effects (Movig et al.,
2004). Samples for analysis can also be reduced by the tendency for drugs to be found in
combination in drivers’ samples. Those who drive after drug use often do so after
consuming multiple drugs or drugs in combination with alcohol, meaning that the samples
for drugs used in isolation are often small (Austroads, 2000; Bates & Blakely, 1999). A
further difficulty associated with culpability studies using fatally injured drivers is that there
is a high baseline for culpability even among the drug free group, with single vehicle crashes
being over-represented in fatal crash data. Longo et al. (2000b) note that in their study of
injured drivers, 53 percent of drug free drivers were culpable for their crashes, compared to
68 percent of the fatally injured drivers in the study by Terhune et al. (1992) and 70 percent
in Drummer’s (1994) study. This also makes it difficult to demonstrate an increased
likelihood of crash culpability with drug use (Dussault et al., 2002; Longo et al., 2000b).
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4 Summary and conclusions
Cannabis is a mostly recreational drug that is known to produce dose-related decrements in
performance on a number of laboratory tasks associated with skills necessary for driving
(e.g. Couper & Logan, 2004). Studies of the effects of cannabis on driving performance
(measured with on-road driving tests and driving simulators) have revealed that it negatively
affects a number of aspects of the driving task but to a lesser degree than it affects
performance in laboratory tasks (Smiley, 1999). Although cannabis is found commonly in the
blood of crash-involved drivers, second in frequency only to alcohol, this is likely to be due to
the fact that it is the second most commonly used drug behind alcohol (Kelly et al., 2004),
and so it is necessary to conduct studies in which the crash risk associated with driving
under the influence of cannabis can be determined.
The best way of determining whether a drug is associated with an increased risk of crash
involvement is to conduct a case-control study in which the drug levels detected in crash-
involved drivers are compared with the levels detected in a matched sample of non-crash-
involved drivers. However, those studies that have been conducted are characterised by
methodological flaws that make the interpretation of the results difficult.
Partly as a response to the difficulty of conducting case-control studies, some researchers
have used culpability studies to determine whether cannabis use contributes to crash
involvement. These studies treat crash-involved drivers who were not culpable for their
crashes as a control group against which to compare the drug use of crash-involved drivers
who were culpable for their crashes. The majority have indicated that cannabis is not
associated with an increased likelihood of culpability. However, as for case-control studies
into cannabis and crash involvement, many culpability studies are difficult to interpret
because of methodological problems. There have been two recent Australian studies
(Drummer et al., 2003; Longo et al., 2000b) that have analysed the relationship between
THC measured in the blood and crash culpability. These two studies produced contradictory
results.
In summary, the risk of crash involvement associated with driving under the influence of
cannabis remains to be determined. A number of recent studies have found an increased
risk of crashing related to the use of cannabis (Drummer et al., 2003; Dussault et al., 2002;
Mura et al., 2003), while others have found no increased risk (Longo et al., 2000b;
Lowenstein & Koziol-Mclain, 2001; Movig et al., 2004). To resolve the issue, it is necessary
to conduct a case-control study similar to those that have been conducted for alcohol
(Borkenstein et al., 1974; McLean & Holubowycz, 1980). That is, it is necessary to compare
the incidence of cannabis in crash-involved drivers with the incidence in non-crash-involved
drivers matched for potential confounding factors, such as age, gender, time of day, day of
week, direction of travel et cetera (Austroads, 2000; Department of Environment Transport
and the Regions, 2000; Jones, Shinar, & Walsh, 2003; Kalant, 2004). Although attempts
have been made to conduct such studies, they have been beset by methodological flaws
potentially resulting in ‘selection bias’ and ‘information bias’. Ideally, the drug use of cases
and controls would be compared using the same biological matrix, and potential control
group drivers would not be given the option of not participating. The latter methodological
requirement would need the introduction of a system of mandatory roadside drug testing.
Controlling for potential confounders is important because it has been suggested by some
authors (Department of Environment Transport and the Regions, 2000; Lowenstein & Koziol-
Mclain, 2001; Vingilis & Macdonald, 2002; Walsh & Mann, 1999) that any over
representation of indicators of cannabis use among crash-involved drivers may merely
reflect a tendency toward cannabis use for certain groups of drivers (young, male, risk-
taking) who have a high risk of crash involvement irrespective of any drug use. That is, the
characteristics of these drivers may lead them to be more likely to crash and also to be
more likely to use cannabis, rather than the cannabis use being responsible for the crash
involvement. Fergusson and Horwood (2001) investigated this theory in a three year follow-
up study of a cohort of 907 drivers in New Zealand who were aged 18 at the beginning of
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the study. An association was found between self-reported levels of cannabis use and
involvement in at-fault crashes. However, this association disappeared after statistical
control of various driver characteristics (drink driving behaviour, other risky or illegal driving
behaviour, driver attitudes, and gender). The authors concluded that the increased risks of
crash involvement for cannabis users reflected “the characteristics of the young people who
used cannabis rather than the effects of cannabis use on driver performance” (Fergusson &
Horwood, 2001, p703).
Finally, it is important to emphasise that alcohol is still the most important drug in terms of
its contribution to crash involvement worldwide (Alvarez, Del Rio, Sancho, Rams, &
Gonzalez-Luque, 2000; Austroads, 2000; Dussault et al., 2002; Jones et al., 2003;
Mathijssen et al., 2002). Alcohol is found more frequently than cannabis and other drugs in
the blood of crash-involved drivers and analytical studies have found that the crash risk
associated with alcohol far exceeds that associated with drugs. Furthermore, drug-impaired
drivers are frequently also impaired by alcohol, which makes the risks associated with drugs
difficult to isolate from the well-known adverse effects of alcohol. Nonetheless, as noted in
the report by Austroads (2000, piii), cannabis and other drugs “present less of a problem
than alcohol, but this does not mean that they are no problem.” Cannabis may not be as
great a problem as alcohol, but research is still needed, particularly a case-control study, to
determine how great a problem it is and whether steps need to be taken to apprehend
those who combine cannabis use and driving.
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